Skip to content

Effect of DASH on HF Outcomes Heart Failure Status in Older Adults (DASH HF)

Effect of Dietary Approaches to Stop Hypertension Diet on Heart Failure Status in Older Adults

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06296862
Enrollment
38
Registered
2024-03-06
Start date
2024-03-31
Completion date
2025-06-30
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

The purpose of this study is to examine the effect of the Dietary Approaches to Stop Hypertension (DASH) diet has on heart failure status in older adults. This study is important because it may provide a low-cost strategy to help reduce hospitalizations and deaths for heart failure patients. Participants will be adults age 65 and older with heart failure. They will have 4 study visits, each lasting about 2 hours, and will be in the study for 12 weeks. They will also be asked about their dietary consumption 6 times, each time lasting about 45 minutes. All in-person study visits will take place in the Emory GCRC. Participants will have physical exams, body measurements, blood tests, urinalysis, chart review, and answer surveys. They will be randomized to eat only the DASH diet provided to them for 4 weeks either at the beginning or end of their participation in the study. Participants will be recruited from heart failure patients at Emory University Hospital, Emory University Hospital Midtown, and Emory Outpatient Advanced Heart Failure Therapy Center. The total enrollment planned under Emory's oversight, accounting for screen failures and withdrawals, will be n=38 participants. The study team will obtain informed consent prior to the first study visit either in person, or, alternatively, over the phone, if requested by participants. Specimens and data obtained in this study will not be banked for future use.

Interventions

OTHERDietary Approaches to Stop Hypertension Diet

The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets. The chosen 4 week intervention duration phase is consistent with previous research showing positive effects of consuming a sodium-reduced dietary intervention on volume status and is longer than in other studies showing positive effects of DASH diet consumption on cardiac outcomes among HF patients. Potential carryover effects are minimized by a washout period of 4 weeks. The meal plan has been previously developed based on NHLBI guidelines for the DASH diet.

Sponsors

Emory University
CollaboratorOTHER
University of Georgia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to 110 Years
Healthy volunteers
No

Inclusion criteria

* 65+ years of age * Heart failure diagnosis and symptoms, as outlined by the 2021 European Society of Cardiology diagnostic guidelines * Residence within 50 miles of Emory University * Have undergone hemodynamic monitoring device implantation (CardioMEMS, Abbott) * Have received optimized HF therapy for 3+ months post CardioMEMS implantation

Exclusion criteria

* Heart failure-related hospitalization or heart failure medication changes within 1 month * Renal disease stages IV-V * Expected survival \< 12 months * Dementia or Alzheimer's disease * Limited English literacy and communication skills

Design outcomes

Primary

MeasureTime frameDescription
B-natriuretic peptide (BNP)Study visit 1-4Clinically relevant natriuretic peptide

Secondary

MeasureTime frameDescription
N-terminal-proBNP (NT-proBNP)Study visit 1-4Clinically relevant natriuretic peptide
Systolic and Diastolic Pulmonary Artery PressuresPatient-driven measurement data points during intervention/control phase (8 weeks)Early indicator of heart failure complications

Countries

United States

Contacts

Primary ContactElisabeth LP Sattler, PhD, RPh
lilian@uga.edu706-542-1040

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026